Literature DB >> 6178756

Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells.

J Jolivet, R L Schilsky, B D Bailey, J C Drake, B A Chabner.   

Abstract

To determine the pharmacologic importance of methotrexate (MTX) polyglutamates, we examined the formation, retention, and effect of these metabolites in cultured human breast cancer cells. Two cell lines (MCF-7 and ZR-75-B) converted the drug to gamma-polyglutamate derivatives in a dose- and time-dependent reaction. After 24-h incubations with 2 muM MTX, polyglutamates of two to five amino acids in length accounted for 55.4% (51.9 nmol/g) of intracellular drug in the MCF-7 cells and 87.6% (62.4 nmol/g) of drug in ZR-75-B cells. In contrast, MDA-231 cells showed lesser accumulation of MTX, and only 32% (4.06 nmol/g) of the intracellular drug was in the form of polyglutamates, a difference that could only partially be explained by decreased ability of these cells to take up free drug from the medium. When MCF-7 and ZR-75-B cells containing polyglutamates were transferred to drug-free medium for 24 h, 22 and 51% of the total intracellular drug were, respectively, retained in each cell line. The loss of intracellular drug was primarily accounted for by disappearance of parent compound and polyglutamates containing 1-3 additional glutamyl residues. The rates of disappearance from cells decreased with increasing glutamyl chain length. All of the 4-NH(2)-10-CH(3)-PteGlu(5) and 47 and 38% of the 4-NH(2)-10-CH(3)-PteGlu(4) remained in the MCF-7 and ZR-75-B cells, respectively, and could be identified in the cytosol after 24 h in drug-free medium. The retention of MTX polyglutamates in these two cell lines in excess of dihydrofolate reductase binding capacity led to prolonged inhibition of thymidylate synthesis and loss of cell viability after removal of extracellular MTX. After 24-h incubation with 2 muM MTX and an additional 24 h in drug-free medium, [(3)H]deoxyuridine incorporation was still inhibited to 30% of control in the MCF-7 cells and 34.7% of control in ZR-75-B cells; this persistent inhibition was associated with a 30% reduction in cell numbers in each cell line during the 24-h period in drug-free medium. In contrast, [(3)H]deoxyuridine incorporation and cell growth quickly recovered to normal in the MDA-231 cells following removal of 2 muM MTX from the medium after a 24-h incubation. Prolonged inhibition of both thymidylate synthesis and cell growth was observed in this cell line in drug-free medium only after a 24-h incubation with 10 muM MTX, a condition that leads to the synthesis of 11.3 nmol/g of MTX polyglutamates. These studies demonstrate that polyglutamate formation allows a prolonged retention of drug in a noneffluxable form and prolonged inhibition of both thymidylate synthesis and cell growth following removal of extracellular drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6178756      PMCID: PMC371243          DOI: 10.1172/jci110624

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  The mechanism of action of methotrexate. III. Requirement of free intracellular methotrexate for maximal suppression of (14C)formate incorporation into nucleic acids and protein.

Authors:  J C White; S Loftfield; I D Goldman
Journal:  Mol Pharmacol       Date:  1975-05       Impact factor: 4.436

2.  Natural resistance to methotrexate in human acute nonlymphocytic leukemia.

Authors:  J R Bertino; W L Sawicki; A R Cashmore; E C Cadman; R T Skeel
Journal:  Cancer Treat Rep       Date:  1977-07

3.  A human cell line from a pleural effusion derived from a breast carcinoma.

Authors:  H D Soule; J Vazguez; A Long; S Albert; M Brennan
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

4.  Breast tumor cell lines from pleural effusions.

Authors:  R Cailleau; R Young; M Olivé; W J Reeves
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

5.  Polygammaglutamyl metabolites of methotrexate.

Authors:  C M Baugh; C L Krumdieck; M G Nair
Journal:  Biochem Biophys Res Commun       Date:  1973-05-01       Impact factor: 3.575

6.  Synthesis and biological evaluation of poly-gamma-glutamyl derivatives of methotrexate.

Authors:  M G Nair; C M Baugh
Journal:  Biochemistry       Date:  1973-09-25       Impact factor: 3.162

7.  Competitive protein binding assay for methotrexate.

Authors:  C E Myers; M E Lippman; H M Elliot; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

8.  Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells.

Authors:  V M Whitehead
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

9.  Tissue-specific synthesis of methotrexate polyglutamates in the rat.

Authors:  V M Whitehead; M M Perrault; S Stelcner
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

10.  The application of rapid kinetic techniques to the transport of thymidine and 3-O-Methylglucose into Mammalian cells in suspension culture.

Authors:  R M Wohlhueter; R Marz; J C Graff; P G Plagemann
Journal:  J Cell Physiol       Date:  1976-12       Impact factor: 6.384

View more
  31 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

Review 2.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.

Authors:  Ryan S Funk; Leon van Haandel; Mara L Becker; J Steven Leeder
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

Review 4.  Polyglutamation of methotrexate. Is methotrexate a prodrug?

Authors:  B A Chabner; C J Allegra; G A Curt; N J Clendeninn; J Baram; S Koizumi; J C Drake; J Jolivet
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

Review 5.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

6.  Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.

Authors:  S Koizumi; G A Curt; R L Fine; J D Griffin; B A Chabner
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

Review 7.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

9.  Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells.

Authors:  R L Schilsky; F S Ordway
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.

Authors:  C J Allegra; J C Drake; J Jolivet; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.